-

Nucleix to Premiere Data on its EpiCheck® Lung Cancer Atlas at the 2023 American Association for Cancer Research Annual Meeting

Presentations will highlight company’s multiomic, genome-wide discovery platform with methylation at its core, to identify blood-based biomarkers focused on early-stage lung cancer detection

SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, will premiere data from its early lung cancer detection discovery platform, the Nucleix EpiCheck® Lung Atlas, at the American Association for Cancer Research (AACR) Annual Event in Orlando, April 14-19. The proprietary Lung Atlas was constructed and developed as part of a multi-institutional effort to map epigenetic and genomic changes associated with early-stage lung cancer, particularly stage I disease.

Presentations at AACR include:

“When lung cancer is detected early, it is more likely that patients will survive the disease,” said Chris Hibberd, CEO, Nucleix. “Currently though, most patients are diagnosed with late-stage cancer, even though research has shown that five-year survival rates are up to 10 times greater when lung cancer is detected early.i Results demonstrate the strength of Nucleix’s Lung EpiCheck assay and our differentiated approach for the discovery and identification of novel biomarkers for non-invasive lung cancer screening. We are leveraging these findings to advance a new generation of Lung EpiCheck, which incorporates novel markers from the Lung Atlas and is optimized to detect minute cancer epigenetic signals with greater sensitivity. The next step is well underway as we evaluate the new assay in the Sightline Trial, a 5,000 patient multicenter study in high-risk current and former smokers.”

Currently there are limited options for early lung cancer detection and only 10% of the nearly 15 million high-risk smokers recommended to receive low-dose CT imaging adhere to current guidelines.ii The Lung Atlas will aid in Nucleix’s development of the next generation of clinical assays. Nucleix’s Lung EpiCheck analyzes changes in multiple methylation markers to screen for lung cancer using a non-invasive blood sample, with a focus on testing individuals who are at high-risk based on smoking history. Lung EpiCheck has been optimized to focus on sensitivity, so that physicians have a better chance of early detection and patients have a better chance of successful treatment.

Learn more about Nucleix’s Lung EpiCheck.

About Nucleix

Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection at a time when intervention can bring the greatest impact for patients. Leveraging NGS and PCR-based technologies, the Company’s pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. The Company’s non-invasive EpiCheck® delivers highly accurate and sensitive results, while providing a seamless testing option for physicians, patients, and the healthcare system. The Company is building an EpiCheck® franchise, beginning with the Bladder EpiCheck® kit, CE-marked and available in Europe for primary and recurrent bladder cancer and upper tract urinary cancer. The Company is advancing its Lung EpiCheck® test towards commercialization for high-risk individuals, while evaluating additional tests for other high-risk diseases. For more information, please visit: https://www.nucleix.com.

i American Lung Association. Lung Cancer Fact Sheet. 2020; https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/resource-library/lung-cancer-fact-sheet

ii U.S. Preventive Services Task Force. Lung Cancer: Screening. 2021; https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening

Contacts

Jake Robison
Evoke Canale
(619) 849-5383
jake.robison@evokegroup.com

Nucleix


Release Versions

Contacts

Jake Robison
Evoke Canale
(619) 849-5383
jake.robison@evokegroup.com

More News From Nucleix

Nucleix to Present Data Showcasing Performance and Clinical Utility of Bladder EpiCheck® Monitoring in Non-Muscle Invasive Bladder Cancer (NMIBC) Recurrence at AUA 2025

SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, will present data from an abstract describing the implications of applying the company’s Bladder EpiCheck® urine test as an adjunct to routine surveillance by white light cystoscopy in all high-risk non-muscle invasive bladder cancer (NMIBC) patients at the American Urological Association's (AUA) 2025 Annual Meeting in Las Vegas, Nevada. “These findin...

NHS Lothian and Nucleix Presented Data at EAU25 Showcasing Potential of Bladder EpiCheck® to Improve Detection of Disease Recurrence in Non-Muscle Invasive Bladder Cancer (NMIBC) Patients

EDINBURGH, Scotland & SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--NHS Lothian, Scotland’s second largest health authority providing a comprehensive range of primary, community-based and acute hospital services, and Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from an abstract featuring Nucleix’s Bladder EpiCheck® test presented at the 46th Annual European Association of Urology (EAU) Congress. The abstract titled “Bla...

A. Menarini Diagnostics and Nucleix Announce a Strategic Partnership for a Non-Invasive Bladder Cancer Test in Europe

FLORENCE, Italy & SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--A. Menarini Diagnostics, a company bringing advanced solutions to the in vitro diagnostic market, and Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, announced at the 36th European Congress of Pathology in Florence, that they have entered into a long-term commercial agreement for the exclusive distribution of the Bladder EpiCheck® test in Europe. This non-invasive CE-marked test d...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.